Brain Bleeds on Blood Thinners: New Guideline Reshapes Emergency Reversal Strategy

Millions of people worldwide take anticoagulant and antiplatelet drugs to prevent strokes, heart attacks, and clots in the veins of their legs and lungs. These medications save lives every day, but they carry a devastating downside: when bleeding occurs inside the brain, the same drug that protects the heart can turn a small hemorrhage into a catastrophic, expanding hematoma. Deciding how, and whether, to rapidly reverse these drugs in the emergency setting has long been one of the most consequential judgment calls in acute neurology and critical care. Now, the Neurocritical Care Society and the Society of Critical Care Medicine have issued a focused update to their influential 2016 guideline on treating antithrombotic-associated intracranial hemorrhage in adults, and an accompanying commentary by Jennifer A. Frontera of New York University Grossman School of Medicine, published in the journal Neurocritical Care, offers a candid appraisal of what has changed and what remains uncertain.

The new guideline represents a substantial methodological step forward. Where the 2016 document relied on more traditional evidence appraisal, the update applies stringent Grading of Recommendations Assessment, Development, and Evaluation criteria, the current international standard for evaluating the certainty of medical evidence. The authors also performed formal meta-analyses, pooling data across studies to generate more precise estimates of benefit and harm. Five specific questions, framed in the PICO format of population, intervention, comparison, and outcome, structured the effort: whether andexanet alfa outperforms prothrombin complex concentrates for reversing direct factor Xa inhibitors; whether desmopressin helps patients on antiplatelet drugs; whether platelet transfusion improves outcomes; whether coagulopathy reversal benefits patients with very small hemorrhages; and whether viscoelastic hemostatic testing, such as thromboelastography and rotational thromboelastometry, meaningfully improves mortality, functional recovery, thrombosis rates, hemorrhage expansion, or treatment-related adverse events. Recommendations were further stratified by whether the bleeding was spontaneous or traumatic, an important distinction that reflects growing recognition that these two patient populations behave differently.

Notably, the update deliberately left many of the 2016 recommendations untouched. Reversal strategies for vitamin K antagonists such as warfarin, direct thrombin inhibitors, unfractionated heparin, low molecular weight heparin, pentasaccharides, and thrombolytics were not re-reviewed, largely because no compelling new literature had emerged that would substantively alter the prior guidance. That decision itself carries information: a decade of research has reshaped thinking in some corners of antithrombotic reversal while leaving others remarkably stable. The most dramatic shifts concern the factor Xa inhibitor antagonists, the class of oral anticoagulants that includes apixaban and rivaroxaban and that has steadily displaced warfarin in clinical practice.

The spotlight falls squarely on andexanet alfa, a recombinant decoy protein engineered to bind factor Xa inhibitors in the bloodstream and neutralize their anticoagulant effect. Early enthusiasm was fueled by the ANNEXA-4 study, which demonstrated that andexanet effectively reduced expansion of intraparenchymal hematomas. Yet adoption was hampered from the outset by the drug’s extraordinarily high cost, and Frontera’s own prior work quantified just how stark the price gap is compared with prothrombin complex concentrates, the four-factor blood products that have long served as the workhorse reversal agent. The pivotal test arrived with ANNEXA-I, a randomized trial that pitted andexanet against usual care, with 86 percent of the comparator group receiving prothrombin complex concentrates. Andexanet achieved significantly better hemostatic efficacy, but that win came with a sobering price: a 5 percent absolute increase in thrombotic events within 30 days, driven particularly by ischemic strokes. Mortality and functional outcomes showed no difference between the arms, leaving clinicians facing an uncomfortable question about which harm matters more, ongoing hematoma expansion or a treatment-emergent ischemic stroke.

The new guideline’s meta-analyses sharpened that trade-off into hard numbers. Pooling the available data suggested a modest but statistically significant 9 percent relative improvement in hemostatic efficacy for andexanet over prothrombin complex concentrates. Against that benefit stood a significant 35 percent relative increase in thrombotic events. Further meta-analyses found no mortality or functional outcome advantage for andexanet, and, perhaps most strikingly for health systems, both hospital and intensive care unit lengths of stay were longer when andexanet was used. The pharmacology helps explain the thrombosis signal: andexanet does not simply remove apixaban or rivaroxaban from the body, it floods the circulation with inert decoys that also bind endogenous tissue factor pathway inhibitor, transiently unleashing coagulation beyond the point of simple reversal. Weighing all of this, the Neurocritical Care Society recommendation now diverges sharply from its European counterpart, the European Stroke Organisation and the European Association of Neurosurgical Societies, whose expert consensus still suggests considering andexanet in adults with spontaneous intracranial hemorrhage on factor Xa inhibitors who present within 15 hours of their last dose, or with proven anti-factor Xa activity above 100 nanograms per milliliter, and within 12 hours of symptom onset. Frontera notes that the European position rests primarily on the ANNEXA-I trial alone, whereas the North American guideline synthesized multiple meta-analyses. The situation is further complicated by market reality: andexanet is no longer available in the United States as of December 2025, though it remains accessible elsewhere in the world, meaning that international practitioners must still navigate these conflicting recommendations at the bedside.

A second provocative question addressed by the guideline is whether anticoagulation reversal should be abandoned for very small hemorrhages, defined here as an intraparenchymal hematoma volume of 10 milliliters or less. The intuition seems reasonable: if a bleed is tiny, perhaps the risks of procoagulant reversal, including thrombosis, outweigh any benefit. But the trial data undercut that logic in an unexpected way. The median hematoma volume in ANNEXA-I was only 10 milliliters, and just 13 milliliters in the earlier INCH trial of vitamin K antagonist reversal. Both studies demonstrated improvements in laboratory measures of coagulopathy and reductions in hematoma expansion, suggesting that even small hemorrhages benefit from reversal. Paradoxically, the data gap lies at the other end of the spectrum: patients with very large hemorrhages were typically excluded from randomized trials, so clinicians managing the sickest patients have the least rigorous evidence to guide them.

The biology of hemorrhage location adds another layer of nuance. The same volume of blood wreaks very different degrees of damage depending on where it accumulates in the brain. A recent analysis cited in the commentary identified volume thresholds that predict poor 90-day outcomes, defined as modified Rankin scores of 4 through 6, and found that the critical threshold is substantially lower for deep hemorrhages, at 17 milliliters or more, than for lobar hemorrhages, at 36 milliliters or more. A deep bleed near critical structures such as the brainstem can be catastrophic at volumes that would be survivable in a lobar location. In other words, even modest expansion of a small deep hemorrhage could translate into substantially worse functional outcomes, which strengthens the argument that initial volume alone should not determine whether reversal is offered. Timing matters too: the time from last known well and the time since the last antithrombotic dose are key predictors of expansion, as are imaging biomarkers such as the spot sign on contrast-enhanced CT, which identifies active extravasation.

The temporal dynamics of risk provide perhaps the most persuasive clinical argument in the commentary. Within the first 48 hours after an intracerebral hemorrhage begins, the risk of hematoma expansion dwarfs the thromboembolic risk of temporarily stopping antithrombotic therapy. The danger of ischemic events off anticoagulation rises only in a delayed fashion, after several days. Even patients at extremely high thromboembolic risk, including those with mechanical heart valves and left ventricular assist devices, appear to tolerate anticoagulation reversal well, with low thromboembolic rates during the first 7 to 14 days after hemorrhage onset. Given that these are the very patients for whom clinicians most fear withholding anticoagulation, the evidence suggests the acute reversal decision can be made with relative confidence. Although the guideline authors judged the data insufficient to issue a formal recommendation on reversal for small-volume hemorrhages, Frontera argues that offering reversal in the acute window, when expansion risk peaks, is prudent regardless of initial volume or the original indication for anticoagulation.

The final significant shift concerns desmopressin, commonly known as DDAVP, a vasopressin analog that increases circulating levels of von Willebrand factor and factor VIII and has been proposed as a hemostatic agent for patients bleeding while on antiplatelet drugs such as aspirin and clopidogrel. The 2016 guideline had conditionally recommended DDAVP on the basis of low-quality evidence. Applying rigorous GRADE criteria to the accumulated data, the new meta-analyses found no significant benefit for hematoma expansion, mortality, functional outcome, or length of stay, and the guideline therefore makes no recommendation either for or against the drug. Importantly, serious adverse events were similar with and without desmopressin, both in the pooled analyses and in the DASH trial, a randomized, placebo-controlled feasibility study from the United Kingdom that established the safety foundation for a definitive phase III investigation. Both the North American and European guidelines urge enrollment of eligible patients in trials testing desmopressin’s utility, though no such phase III study is currently open. In the interim, Frontera observes that the trend toward less expansion, the demonstrated safety record, the low cost, the mechanistic plausibility, and the absence of alternative hemostatic options for antiplatelet-associated bleeding may reasonably lead practitioners to prescribe it anyway, a rare instance of a guideline update explicitly acknowledging the gap between evidence and bedside reality. The broader message is clear: for traumatic brain injury-related hemorrhage and for hemostatic agents in antiplatelet bleeding, the field still needs well-designed trials before certainty can replace consensus.

Subject of Research: Emergency reversal of antithrombotic therapy in adult intracranial hemorrhage per a 2026 neurocritical care guideline update

Article Title: Commentary on: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and Society of Critical Care Medicine

Article References: Commentary on: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and Society of Critical Care Medicine. (n.d.). https://doi.org/10.1007/s12028-026-02639-4

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02639-4

Keywords: intracranial hemorrhage, anticoagulation reversal, andexanet alfa, prothrombin complex concentrate, desmopressin, factor Xa inhibitors, hematoma expansion, Neurocritical Care Society, GRADE methodology, antiplatelet therapy, thromboembolism, viscoelastic testing